Senseonics Holdings, Inc. - Q2 2024 10-Q Summary
Business Context and Reporting Period
This report covers the quarterly period ended June 30, 2024. Senseonics Holdings, Inc. is a medical technology company focused on developing and manufacturing long-term, implantable continuous glucose monitoring (CGM) systems, primarily the Eversense platform. The company operates in a single segment and relies heavily on a commercialization agreement with Ascensia Diabetes Care Holdings AG for distribution.
Key Financial Metrics
| Metric (in thousands) | Q2 2024 | Q2 2023 | 6 Months 2024 | 6 Months 2023 |
|---|---|---|---|---|
| Total Revenue | $4,865 | $4,126 | $9,912 | $8,263 |
| Gross Profit | $298 | $417 | $633 | $830 |
| Gross Margin | 6.1% | 10.1% | 6.4% | 10.0% |
| Operating Loss | $(19,493) | $(19,868) | $(37,724) | $(39,578) |
| Net Loss | $(20,287) | $(20,423) | $(39,164) | $(19,099) |
| Cash & Equivalents | $34,853 | N/A | N/A | N/A |
| Short-term Investments | $49,774 | N/A | N/A | N/A |
| Total Liquidity | $84,627 | N/A | N/A | N/A |
| Total Debt (Current + Long-term) | $52,844 | N/A | N/A | N/A |
Note: Q2 2023 Net Loss was significantly impacted by a one-time gain on debt exchange in the prior year's six-month period, making the six-month comparison volatile.
Material Changes vs. Prior Period
- Revenue Growth: Total revenue increased 18% year-over-year for the quarter ($4.9M vs $4.1M) and 20% for the six months ($9.9M vs $8.3M), driven by increased commercial activity and new patient adoption.
- Margin Compression: Gross margin declined to 6.1% in Q2 2024 from 10.1% in Q2 2023. This decrease is attributed to higher fixed manufacturing costs and an increased revenue share percentage paid to Ascensia.
- Expense Management: R&D expenses decreased by $2.0M in Q2 2024 compared to the prior year, primarily due to the completion of clinical trials for the 365-day product. SG&A expenses increased by $1.5M, driven by personnel costs (stock-based compensation) and legal fees related to commercial expansion.
- Debt Structure: The company funded Tranche 2 of its Loan and Security Agreement in January 2024, adding $10.0M to its term loan facility. Total debt carrying value is approximately $52.8M as of June 30, 2024.
Outlook, Risks, and Management Commentary
- Going Concern Warning: Management has determined that substantial doubt exists regarding the company's ability to continue as a going concern for the twelve months following the issuance of these financial statements. The company expects existing cash and marketable securities ($84.6M) to be insufficient to fund operations and meet debt covenants through Q2 2025 without additional funding.
- Liquidity Strategy: The company plans to seek additional capital through public or private debt and equity financings, collaborations, or strategic alliances. There is no assurance such funding will be available on acceptable terms.
- Product Pipeline: The company submitted an FDA 510(k) application in May 2024 for a new 365-day sensor with once-per-week calibration. First-in-human testing for the "Gemini" system (a 2-in-1 glucose monitoring system) began in July 2024.
- Legal Proceedings: In May 2024, the company was sued by Cellspin Soft, Inc., alleging patent infringement. The company intends to vigorously defend the lawsuit, noting that the validity of the patents in question is currently being challenged.
- Customer Concentration: The company remains highly dependent on Ascensia, which accounted for 84% of total revenue in Q2 2024.
Investor Verification Checklist
- Cash Runway: Verify the sufficiency of the $84.6M liquidity position against the stated need for additional funding before Q2 2025.
- Debt Covenants: Review the specific performance milestones and minimum cash requirements under the Loan and Security Agreement with Hercules Capital to assess default risk.
- Revenue Share Terms: Investigate the specific terms of the revenue share agreement with Ascensia that contributed to the gross margin decline.
- Patent Litigation: Monitor the status of the Cellspin Soft, Inc. lawsuit and the Inter Partes Review proceedings regarding the validity of the asserted patents.
- Regulatory Status: Track the FDA review timeline for the 365-day sensor 510(k) submission and the progress of the Gemini system clinical trials.